ArticleBritish journal of haematology2026

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial.

Rami S Komrokji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.